EDIT
Editas Medicine, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.23
+4.87%Year over year
Reported trailing growth
- Revenue
- +20.8%
- EBITDA
- +67.3%
- EBIT
- +65.8%
- EPS
- +73.8%
- Free cash flow
- +41.2%
- Operating cash flow
- +40.5%
Forward estimates
Based on analyst estimates
- Revenue
- -62.9%
- EBITDA
- -22.7%
- EPS
- +1.3%
Three-year CAGR
- Revenue
- +27.1%
- EBITDA
- +36.2%
- EBIT
- +60.4%
- Net income
- +32.5%
- EPS
- +37.5%
- Free cash flow
- +24.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026